Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

Inclusion Criteria:

• Must be at least 18 years old
• Must have been diagnosed with advanced or metastatic non-small cell lung cancer
• Must be able to visit the doctor's office every 28 days for 6 months or longer.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Have other significant medical problems as determined by your physician
• Are unable to swallow tablets
• Have a history of significant heart disease